Health Care • Biotechnology: Pharmaceutical Preparations
$70.67 ▼ -1.33
(-1.85%)
MKT CAP: $1.65B • VOL: 514.7K
52W L $70 52W H $96
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$59
MEDIAN
$79
MEAN
$81
HIGH
$96
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ANIP TAPE
ANIP // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $85.51 | $81.27 | 2025-02-14 | $64.31 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $89.04 | $83.39 | 2025-02-06 | $66.43 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $80.56 | $77.74 | 2025-01-29 | $67.84 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $72.08 | — | 2025-01-17 | $69.26 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $62.19 | $67.14 | 2025-01-09 | $62.90 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $84.10 | $73.50 | 2024-12-18 | $61.48 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $68.55 | $71.38 | 2024-12-04 | $65.72 | -4.3% | 48% | C |